newsfilter
← Latest News
ACCESS Newswire·

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancersStrategic focus on exploratory investigator-initiated clinical studies with institutional